Viridian Therapeutics, Inc./DE Contract Liability (Deferred Revenue)
Viridian Therapeutics, Inc./DE (VRDN) had Contract Liability (Deferred Revenue) of $181.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Current $181.00K.
- 2026-03-31: Contract with Customer, Liability, Current $274.00K.
- 2025-12-31: Contract with Customer, Liability, Current $367.00K.
- 2025-09-30: Contract with Customer, Liability, Current $372.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $181.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $274.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $367.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $372.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $288.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $288.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $288.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $288.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $288.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $288.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $288.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $288.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $288.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $288.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $288.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $288.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $288.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $288.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $289.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $288.00K 10-Q · filed 2021-11-05 |
| 2021-06-30 | $288.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $288.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | $301.00K 10-Q · filed 2021-11-05 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |